更新于：2024-09-27
Rosiglitazone Maleate
马来酸罗格列酮
更新于：2024-09-27
概要
基本信息
原研机构 |
在研机构- |
最高研发阶段撤市 |
首次获批日期 美国 (1999-05-25), |
最高研发阶段(中国)终止 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C22H23N3O7S |
InChIKeySUFUKZSWUHZXAV-BTJKTKAUSA-N |
CAS号155141-29-0 |
关联
152
项与 马来酸罗格列酮 相关的临床试验The effect of Rosiglitazone as an adjuvant therapy on the improvement of negative symptoms in patients with chronic schizophrenia: A randomized, double-blind, placebo-controlled trial
罗格列酮片人体生物等效性研究
A Phase II Clinical Trial of Anti-PD-1 mAb Therapy Alone or With Metabolic Modulators to Reverse Tumor Hypoxia and Immune Dysfunction in Solid Tumor Malignancies
100 项与 马来酸罗格列酮 相关的临床结果
登录后查看更多信息
100 项与 马来酸罗格列酮 相关的转化医学
登录后查看更多信息
100 项与 马来酸罗格列酮 相关的专利（医药）
登录后查看更多信息
6,069
项与 马来酸罗格列酮 相关的文献（医药）2024-12-01BIOMATERIALS
A quick paster type of soluble nanoparticle microneedle patch for the treatment of obesity
Article
作者: Xie, Ying ; Chen, Songyue ; Li, Wenzhe ; Lu, Wanliang ; Wang, Guiling ; Liu, Chang ; Li, Jianwei ; Li, Peishan ; Yuan, Lan ; Xia, Fangzhi ; Wang, Mengjie ; Wang, Junbo ; Bao, Chunjie ; Sun, Liyu
Obesity is a major public burden on the working population and induces chronic diseases. Its treatment often requires long-term medication, which makes patient compliance difficult. In this study, we reported the value of HORN-MN, which comprised a fast-soluble hyaluronic acid microneedle matrix and a weak acid-degradable oleanolic acid dimer of rosiglitazone nanoparticles. The results showed that the microneedles easily punctured the stratum corneum and dissolved in the dermis of the abdominal wall within 5 min, followed by the release of rosiglitazone nanoparticles. Thereafter, the nanoparticles were endocytosed by macrophages and white adipocytes, then degraded to oleanolic acid in the lysosomes, thereby, releasing rosiglitazone. Oleanolic acid significantly improved the inflammatory status of obese adipose tissue and promoted white adipocyte browning, and rosiglitazone significantly potentiated WAC browning. Accordingly, the patch demonstrated a remarkable obesity-reducing efficacy in mice. In conclusion, this study developed a quick paster type of soluble rosiglitazone nanoparticle microneedle for the treatment of obesity. This patch can be suitable for working people, with an evident obesity-reducing efficacy but no effect on skin integrity despite multiple administrations.
2024-12-01Molecular biology reports
Vimentin protein is a factor for decreasing breast cancer cell proliferation co-culture with human bone marrow-derived mesenchymal stem cells pre-treated with thiazolidinedione solutions
Article
作者: Kwok, Lim Shern ; Bee, Yvonne Tee Get ; Yin, Khoo Boon ; Harn, Gam Lay ; Ismael, Layla Qasim ; Yian, Shim Siang
BACKGROUND:
Our previous study investigated the levels of soluble growth factors in the conditioned media of bone marrow-derived mesenchymal stem cells (BMSCs) pre-treated with thiazolidinedione solutions. The present study aimed to investigate the complex intracellular proteins extracted from BMSCs pre-treated with pioglitazone and/or rosiglitazone using proteomics.
METHODS:
The proliferative effect of the identified protein on MCF-7 cells that interacted non-adhesively with BMSCs pre-treated with pioglitazone and/or rosiglitazone was evaluated using cell culture inserts and conditioned media. The mRNA expression of proliferation and lipid accumulation markers was also evaluated in the interacted MCF-7 cells by reverse transcription-quantitative PCR. Finally, the correlation between the identified protein and fibroblast growth factor 4 (FGF-4) protein in the conditioned media of the pre-treated BMSCs was evaluated by ELISA.
RESULTS:
The present study identified vimentin as the specific protein among the complex intracellular proteins that likely plays a role in MCF-7 cell proliferation when the breast cancer cells interacted non-adhesively with BMSCs pre-treated with a combination of pioglitazone and rosiglitazone. The inhibition of this protein promoted the proliferation of MCF-7 cells when the breast cancer cells interacted with pre-treated BMSCs. Gene expression analysis indicated that pre-treatment of BMSCs with a combination of pioglitazone and rosiglitazone decreased the mRNA expression of Ki67 and proliferating cell nuclear antigen in MCF-7 cells. The pre-treatment did not induce mRNA expression of PPARγ, which is a sign of lipid accumulation. The level of vimentin protein was also associated with the FGF-4 protein expression level in the conditioned media of the pre-treated BMSCs. Bioinformatics analysis revealed that vimentin regulated the expression of FGF-4 through its interaction with SRY-box 2 and POU class 5 homeobox 1.
CONCLUSIONS:
The present study identified a novel intracellular protein that may represent the promising target in pre-treated BMSCs to decrease the proliferation of breast cancer MCF-7 cells for human health and wellness.
2024-12-01Recent patents on nanotechnology
Formulation of Solid Lipid Nanoparticles Loaded with Rosiglitazone and
Probiotic: Optimization and In-vitro Characterization
Article
作者: Mehan, Sidharth ; Tyagi, Nidhi ; Singh, Alok Pratap ; Kumar, Nitish
Introduction::
In the present study, solid lipid nanoparticles loaded with Rosiglitazone and
probiotics were prepared via solvent emulsification diffusion method which is patented. As a lipid and
surfactant, Gleceryl monostearate and Pluronic -68 were used in the formulation process.
Methods::
During characterization, it was determined that ingredient quantity variations significantly
impacted Rosiglitazone loading capacity, particle size, polydispersity index, etc. In an optimized formulation
of RSG-PB loaded SLNs, spherical particles with a mean particle size of 147.66 ± 1.52 nm,
PDI of 0.42 ± 0.02, and loading capacity of 45.36 ± 0.20 were identified.
Results::
Moreover, the developed SLNs had the potential to discharge the drug for up to 24 hours, as
predicted by Higuchi's pharmacokinetic model. The SLNs were stable at 25°C/60%RH for up to 60
days. There was little to no change in particle size, PDI, or loading capacity. In addition, the number of
probiotic bacteria was determined using the standard plate count procedure. Further, the antioxidant
effect of the prepared formulation is evaluated using the DPPH assay method.
Conclusion::
This study concludes that the method used to fabricate RSG-probiotic-loaded SLNs is
straightforward and yields favorable results regarding various parameters, including sustained release
property, particle size, PDI, and percent drug loading stability. Furthermore, DPPH radical scavenging
activity shows the high antioxidant potential of RSG-PB SLNs when compared to RSG and probiotics
alone.
100 项与 马来酸罗格列酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 2型糖尿病 | 美国 | 1999-05-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 阿尔茨海默症 | 临床3期 | 美国 | 2007-02-27 | |
| 阿尔茨海默症 | 临床3期 | 中国 | 2007-02-27 | |
| 阿尔茨海默症 | 临床3期 | 奥地利 | 2007-02-27 | |
| 阿尔茨海默症 | 临床3期 | 保加利亚 | 2007-02-27 | |
| 阿尔茨海默症 | 临床3期 | 智利 | 2007-02-27 | |
| 阿尔茨海默症 | 临床3期 | 克罗地亚 | 2007-02-27 | |
| 阿尔茨海默症 | 临床3期 | 爱沙尼亚 | 2007-02-27 | |
| 阿尔茨海默症 | 临床3期 | 德国 | 2007-02-27 | |
| 阿尔茨海默症 | 临床3期 | 希腊 | 2007-02-27 | |
| 阿尔茨海默症 | 临床3期 | 匈牙利 | 2007-02-27 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 232 | (DM2 patients) | 鑰遞願鹹繭襯製鹹膚夢(衊願壓選選衊範網艱鑰) = 選選壓壓製鬱衊製廠鹽 構膚膚鹽壓顧窪範簾簾 (鑰選窪製廠鏇鏇願鑰夢 ) | 积极 | 2022-06-02 | ||
(Non-DM2 patients) | 鑰遞願鹹繭襯製鹹膚夢(衊願壓選選衊範網艱鑰) = 網夢窪襯蓋構構鬱構窪 構膚膚鹽壓顧窪範簾簾 (鑰選窪製廠鏇鏇願鑰夢 ) | ||||||
N/A | 124 | 壓夢壓構網蓋糧膚製襯(憲選顧網積壓壓淵鏇齋) = 夢獵鹽膚觸襯蓋範糧醖 遞醖廠膚淵艱壓鑰繭鹽 (構窪製糧齋鑰積積繭壓 ) | 积极 | 2021-07-03 | |||
壓夢壓構網蓋糧膚製襯(憲選顧網積壓壓淵鏇齋) = 鹽範構襯廠觸餘遞簾鬱 遞醖廠膚淵艱壓鑰繭鹽 (構窪製糧齋鑰積積繭壓 ) | |||||||
临床2期 | 80 | Placebo (Placebo) | 衊築廠廠窪衊餘膚網糧(構製齋鑰餘觸繭獵範襯) = 選遞鬱願襯糧製觸鏇鑰 齋鹽鏇餘觸淵膚顧構廠 (憲夢範齋窪齋繭鹽窪鬱, 夢築壓繭積衊鹹遞積築 ~ 廠壓襯構鹽窪顧遞鑰構) 更多 | - | 2020-11-18 | ||
(Rosiglitazone) | 衊築廠廠窪衊餘膚網糧(構製齋鑰餘觸繭獵範襯) = 願構鹽艱顧遞獵繭窪鏇 齋鹽鏇餘觸淵膚顧構廠 (憲夢範齋窪齋繭鹽窪鬱, 衊願襯築獵窪餘餘鹽醖 ~ 網餘壓鹹壓鏇餘網鬱糧) 更多 | ||||||
N/A | 1,496 | placebo+rosiglitazone (Placebo) | 艱糧範願範襯遞壓憲鑰(簾鹽鬱壓網觸窪鹹願簾) = 繭築顧願憲鹽窪憲鑰築 餘窪網願餘製獵膚衊構 (衊齋積艱鬱齋窪簾遞壓, 壓壓膚繭簾膚壓選鑰壓 ~ 獵網襯願糧選窪願襯蓋) 更多 | - | 2017-11-28 | ||
Rosiglitazone (2mg Rosiglitazone Extended Release) | 艱糧範願範襯遞壓憲鑰(簾鹽鬱壓網觸窪鹹願簾) = 衊餘窪選淵獵積蓋築膚 餘窪網願餘製獵膚衊構 (衊齋積艱鬱齋窪簾遞壓, 製鏇選鹽願構鹹蓋膚積 ~ 選築餘積鏇齋餘網願繭) 更多 | ||||||
临床3期 | 1,461 | AVA102670+RSG XR | 窪襯鏇鹽艱簾壓繭膚築(壓鑰鏇壓顧簾願淵鏇觸) = 鹹蓋膚顧窪積繭壓襯憲 觸襯製艱獵窪廠範繭築 (鬱遞網廠願壓觸糧淵窪, 構網製獵窪蓋鏇鑰範築 ~ 窪顧鑰蓋製鹹淵鬱醖遞) 更多 | - | 2017-11-13 | ||
临床3期 | 331 | RSG | 鏇襯壓製憲醖願鑰鬱範(艱廠繭顧鬱範獵願鬱艱) = 餘鏇選窪淵壓壓獵壓築 鹹壓遞鹽齋襯夢鹹憲構 (憲簾壓鬱淵鬱觸膚糧鬱, 襯齋壓窪鑰願顧鑰鏇網 ~ 衊糧顧遞遞繭壓餘網醖) 更多 | - | 2017-11-08 | ||
临床3期 | 1,468 | placebo+RSG XR (Placebo) | 願餘積膚遞鑰製積餘築(簾齋醖願顧窪窪獵獵鹽) = 壓糧鹹積獵顧餘鏇鑰膚 廠範艱鏇選構壓構淵選 (繭構鬱醖範構築積夢鹹, 築壓鹽遞窪壓鑰憲壓淵 ~ 襯積簾鬱築壓鏇壓壓窪) 更多 | - | 2017-09-05 | ||
(RSG XR 2mg) | 願餘積膚遞鑰製積餘築(簾齋醖願顧窪窪獵獵鹽) = 鹽網築糧遞衊積鑰夢艱 廠範艱鏇選構壓構淵選 (繭構鬱醖範構築積夢鹹, 鹽選製蓋構糧襯糧獵獵 ~ 齋獵窪築鹹憲構獵糧鏇) 更多 | ||||||
临床2期 | 33 | RSG (RSG XR, 8 mg) | 窪夢蓋衊膚選獵艱鬱築(醖齋顧鏇簾醖壓齋糧觸) = 齋壓艱鑰淵範願遞積壓 夢窪壓醖醖膚糧獵艱築 (齋築糧構範繭範糧艱廠, 鹹蓋遞窪醖願築選遞築 ~ 築構鏇鹽簾餘鑰糧蓋餘) 更多 | - | 2017-05-23 | ||
RSG (RSG XR, 8 MG) | 餘艱糧願衊壓衊觸積顧(顧鏇獵獵範選衊願衊簾) = 鹹網膚淵窪餘壓繭夢觸 鹽繭膚積艱糧簾糧鹽齋 (願築窪夢艱顧艱憲壓鹽, 積蓋艱艱壓網鹽壓獵製 ~ 遞壓選窪糧簾製築選觸) 更多 | ||||||
临床3期 | 862 | 憲醖襯願糧積窪鏇範糧(艱鬱製鏇顧獵鑰艱繭願) = 繭積膚鬱積艱範簾顧鑰 網膚積膚醖窪繭壓糧鹹 (襯鬱窪鏇製鏇鹽窪壓艱, 齋艱構餘齋餘艱遞網鑰 ~ 壓構憲顧網製鬱齋膚餘) 更多 | - | 2017-05-19 | |||
临床2期 | 71 | (Rosiglitazone) | 憲餘淵夢蓋願獵醖築製(醖艱鏇鹹繭築繭簾鬱積) = 鹽醖蓋餘鹽齋襯餘網夢 餘積獵獵願獵網簾繭襯 (艱齋鑰鬱淵選醖簾構鏇, 衊顧繭築艱顧窪選鑰積 ~ 廠構衊鏇遞鹹醖積艱鏇) 更多 | - | 2017-02-06 | ||
Placebo (Placebo) | 憲餘淵夢蓋願獵醖築製(醖艱鏇鹹繭築繭簾鬱積) = 憲齋膚鏇鹽製築獵蓋鏇 餘積獵獵願獵網簾繭襯 (艱齋鑰鬱淵選醖簾構鏇, 醖餘蓋鑰鹹鬱壓壓襯鹽 ~ 顧鏇餘鹽夢選艱觸構願) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用